Discovery of an allosteric inhibitor binding site in 3-oxo-acyl-ACP reductase from pseudomonas aeruginosa

ACS Chemical Biology

Volumn 8, Issue 11, 2013, Pages 2518-2527

  Cukier, Cyprian D ^a   Hope, Anthony G ^b   Elamin, Ayssar A ^c   Moynie, Lucile ^d   Schnell, Robert ^a   Schach, Susanne ^c   Kneuper, Holger ^b   Singh, Mahavir ^c   Naismith, James H ^d   Lindqvist, Ylva ^a   Gray, David W ^b   Schneider, Gunter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c LIONEX DIAGNOSTICS AND THERAPEUTICS GMBH   (Germany)

^d UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 OXO ACYL ACYL CARRIER PROTEIN REDUCTASE; BACTERIAL ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; OXIDOREDUCTASE;

ALLOSTERISM; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; GENE DELETION; HYDROGEN BOND; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN QUATERNARY STRUCTURE; PSEUDOMONAS AERUGINOSA; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CONFORMATION; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GENETICS; IC50; METABOLISM; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC SITE; ANTI-BACTERIAL AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; GENE DELETION; INHIBITORY CONCENTRATION 50; MOLECULAR CONFORMATION; OXIDOREDUCTASES; PSEUDOMONAS AERUGINOSA;

EID: 84887931764     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb4005063     Document Type: Article

References (46)

1. Kerr, K. G. and Snelling, A. M. (2009) Pseudomonas aeruginosa: a formidable and ever-present adversary J. Hosp. Infect. 73, 338-344
2. Mesaros, N., Nordmann, P., Plesiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., Van Laethem, Y., Jacobs, F., Lebecque, P., Malfroot, A., Tulkens, P. M., and Van Bambeke, F. (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium Clin. Microbiol. Infect. 13, 560-578
3. Breidenstein, E. B., de la Fuente-Nunez, C., and Hancock, R. E. (2011) Pseudomonas aeruginosa: all roads lead to resistance Trends Microbiol. 19, 419-426
4. Strateva, T. and Yordanov, D. (2009) Pseudomonas aeruginosa-a phenomenon of bacterial resistance J. Med. Microbiol. 58, 1133-1148
5. Hirsch, E. B. and Tam, V. H. (2010) Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes Expert Rev. Pharmacoecon. Outcomes Res. 10, 441-451
6. Fothergill, J. L., Winstanley, C., and James, C. E. (2012) Novel therapeutic strategies to counter Pseudomonas aeruginosa infections Expert Rev. Anti Infect. Ther. 10, 219-235
7. Moynie, L., Schnell, R., McMahon, S. A., Sandalova, T., Boulkerou, W. A., Schmidberger, J. W., Alphey, M., Cukier, C., Duthie, F., Kopec, J., Liu, H., Jacewicz, A., Hunter, W. N., Naismith, J. H., and Schneider, G. (2013) The AEROPATH project targeting Pseudomonas aeruginosa: crystallographic studies for assessment of potential targets in early-stage drug discovery Acta Crystallogr. F69, 25-34
8. Sharma, A., Krause, A., and Worgall, S. (2012) Recent developments for Pseudomonas vaccines Human Vaccines 7, 999-1011
9. Winsor, G. L., Lam, D. K., Fleming, L., Lo, R., Whiteside, M. D., Yu, N. Y., Hancock, R. E., and Brinkman, F. S. (2011) Pseudomonas Genome Database: improved comparative analysis and population genomics capability for Pseudomonas genomes Nucleic Acids Res. 39, D596-600
10. Zhang, M., Su, S., Bhatnagar, R. K., Hassett, D. J., and Lu, L. J. (2012) Prediction and analysis of the protein interactome in Pseudomonas aeruginosa to enable network-based drug target selection PLoS One 7, e41202
11. Chan, D. I. and Vogel, H. J. (2010) Current understanding of fatty acid biosynthesis and the acyl carrier protein Biochem. J. 430, 1-19
12. Goodman, C. D. and McFadden, G. I. (2008) Fatty acid synthesis in protozoan parasites: unusual pathways and novel drug targets Curr. Pharm. Des. 14, 901-916
13. Rock, C. O. and Jackowski, S. (2002) Forty years of bacterial fatty acid synthesis Biochem. Biophys. Res. Commun. 292, 1155-1166
14. Campbell, J. W. and Cronan, J. E., Jr. (2001) Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery Annu. Rev. Microbiol. 55, 305-332
15. Heath, R. J. and Rock, C. O. (2004) Fatty acid biosynthesis as a target for novel antibacterials Curr. Opin. Invest. Drugs 5, 146-153
16. Pan, P. and Tonge, P. J. (2012) Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds Curr. Top. Med. Chem. 12, 672-693
17. Parsons, J. B. and Rock, C. O. (2011) Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? Curr. Opin. Microbiol. 14, 544-549
18. Zhang, Y. M., Lu, Y. J., and Rock, C. O. (2004) The reductase steps of the type II fatty acid synthase as antimicrobial targets Lipids 39, 1055-1060
19. Kavanagh, K. L., Jornvall, H., Persson, B., and Oppermann, U. (2008) Medium- and short-chain dehydrogenase/reductase gene and protein families: the SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes Cell. Mol. Life Sci. 65, 3895-3906
20. Sohn, M. J., Zheng, C. J., and Kim, W.G. (2008) Macrolactin S, a new antibacterial agent with FabG-inhibitory activity from Bacillus sp. AT28 J. Antibiot. (Tokyo) 61, 687-691
21. Tasdemir, D., Lack, G., Brun, R., Ruedi, P., Scapozza, L., and Perozzo, R. (2006) Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids J. Med. Chem. 49, 3345-3353
22. Wickramasinghe, S. R., Inglis, K. A., Urch, J. E., Muller, S., van Aalten, D. M., and Fairlamb, A. H. (2006) Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from Plasmodium falciparum, a key enzyme in fatty acid biosynthesis Biochem. J. 393, 447-457
23. Zhang, F., Luo, S. Y., Ye, Y. B., Zhao, W. H., Sun, X. G., Wang, Z. Q., Li, R., Sun, Y. H., Tian, W. X., and Zhang, Y. X. (2008) The antibacterial efficacy of an aceraceous plant [Shantung maple (Acer truncatum Bunge)] may be related to inhibition of bacterial beta-oxoacyl-acyl carrier protein reductase (FabG) Biotechnol. Appl. Biochem. 51, 73-78
24. Zhang, Y. M. and Rock, C. O. (2004) Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase J. Biol. Chem. 279, 30994-31001
25. Lai, C. Y. and Cronan, J. E. (2004) Isolation and characterization of beta-ketoacyl-acyl carrier protein reductase (fabG) mutants of Escherichia coli and Salmonella enterica serovar Typhimurium J. Bacteriol. 186, 1869-1878
26. Parish, T., Roberts, G., Laval, F., Schaeffer, M., Daffe, M., and Duncan, K. (2007) Functional complementation of the essential gene fabG1 of Mycobacterium tuberculosis by Mycobacterium smegmatis fabG but not Escherichia coli fabG J. Bacteriol. 189, 3721-3728
27. Hoang, T. T., Karkhoff-Schweizer, R. R., Kutchma, A. J., and Schweizer, H. P. (1998) A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants Gene 212, 77-86
28. Hoang, T. T., Kutchma, A. J., Becher, A., and Schweizer, H. P. (2000) Integration-proficient plasmids for Pseudomonas aeruginosa: site-specific integration and use for engineering of reporter and expression strains Plasmid 43, 59-72
29. Price, A. C., Zhang, Y. M., Rock, C. O., and White, S. W. (2001) Structure of beta-ketoacyl-[acyl carrier protein] reductase from Escherichia coli: negative cooperativity and its structural basis Biochemistry 40, 12772-12781
30. Cohen-Gonsaud, M., Ducasse, S., Hoh, F., Zerbib, D., Labesse, G., and Quemard, A. (2002) Crystal structure of MabA from Mycobacterium tuberculosis, a reductase involved in long-chain fatty acid biosynthesis J. Mol. Biol. 320, 249-261
31. Zaccai, N. R., Carter, L. G., Berrow, N. S., Sainsbury, S., Nettleship, J. E., Walter, T. S., Harlos, K., Owens, R. J., Wilson, K. S., Stuart, D. I., and Esnouf, R. M. (2008) Crystal structure of a 3-oxoacyl-(acylcarrier protein) reductase (BA3989) from Bacillus anthracis at 2.4-A resolution Proteins 70, 562-567
32. Subramanian, S., Abendroth, J., Phan, I. Q., Olsen, C., Staker, B. L., Napuli, A., Van Voorhis, W. C., Stacy, R., and Myler, P. J. (2011) Structure of 3-ketoacyl-(acyl-carrier-protein) reductase from Rickettsia prowazekii at 2.25 A resolution Acta Crystallogr. F67, 1118-1122
33. Dutta, D., Bhattacharyya, S., and Das, A. K. (2012) Crystal structure and fluorescence studies reveal the role of helical dimeric interface of staphylococcal fabg1 in positive cooperativity for NADPH Proteins 80, 1250-1257
34. Willett, P., Barnard, J. M., and Downs, G. M. (1998) Chemical similarity searching J. Chem. Inf. Comput. Sci. 38, 983-996
35. Cheng, T., Li, Q., Zhou, Z., Wang, Y., and Bryant, S. H. (2012) Structure-based virtual screening for drug discovery: a problem-centric review AAPS J. 14, 133-141
36. Price, A. C., Zhang, Y. M., Rock, C. O., and White, S. W. (2004) Cofactor-induced conformational rearrangements establish a catalytically competent active site and a proton relay conduit in FabG Structure 12, 417-428
37. Dutta, D., Bhattacharyya, S., Roychowdhury, A., Biswas, R., and Das, A. K. (2013) Crystal structure of hexanoyl-CoA bound to β-ketoacyl reductase FabG4 of Mycobacterium tuberculosis Biochem. J. 450, 127-39
38. Hopkins, A. L., Groom, C. R., and Alex, A. (2004) Ligand efficiency: a useful metric for lead selection Drug Discovery Today 9, 430-431
39. Hann, M. M. and Keserü, G. M. (2012) Finding the sweet spot: the role of nature and nurture in medicinal chemistry Nat. Rev. Drug Discovery 11, 355-365
40. Hopkins, A. L. and Bickerton, R. (2010) Drug discovery: Know your chemical space Nat. Chem. Biol. 6, 482-483
41. Bolton, E. E., Wang, Y., Thiessen, P. A., Bryant, S. H., Ralph, A. W., and David, C. S. (2008) PubChem: Integrated Platform of Small Molecules and Biological Activities, in Annual Reports in Computational Chemistry Vol. 4, 12, pp 217-241, Elsevier, New York.
42. Kim, M. I., Kwon, S. J., and Dordick, J. S. (2009) In vitro precursor-directed synthesis of polyketide analogues with coenzyme a regeneration for the development of antiangiogenic agents Org. Lett. 11, 3806-3809
43. Lapeyre, C., Delomenede, M., Bedos-Belva, l. F., Duran, H., Negre-Salvayre, A., and Baltas, M. (2005) Design, synthesis, and evaluation of pharmacological properties of cinnamic derivatives as antiatherogenic agents J. Med. Chem. 48, 8115-8124
44. Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J., and Wyatt, P. G. (2008) Lessons learnt from assembling screening libraries for drug discovery for neglected diseases ChemMedChem. 3, 435-444
45. Meyer, B. and Peters, T. (2003) NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors Angew. Chem., Int. Ed. 42, 864-890
46. Moynie, L., Leckie, S. M., McMahon, S. A., Duthie, F. G., Koehnke, A., Taylor, J. W., Alphey, M. S., Brenk, R., Smith, A. D., and Naismith, J. H. (2013) Structural insights into the mechanism and inhibition of the beta-hydroxydecanoyl-acyl carrier protein dehydratase from Pseudomonas aeruginosa J. Mol. Biol. 425, 365-377